Ajanta Pharma · NSE: AJANTPHARM · BSE: 532331
Q1 FY25 results · Apr–Jun 2024
Ajanta Pharma reported revenue from operations of ₹1,144.92 crore (up 12.1% from Q1 FY24) and net profit of ₹245.77 crore (up 18.1% from Q1 FY24) for Q1 FY25 (Apr–Jun 2024), on a consolidated basis.
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,144.92 | 1,021.04 | +12.1% | 1,054.08 | +8.6% |
| Other income | 26.47 | 31.75 | −16.6% | 35.50 | −25.4% |
| Total income | 1,171.39 | 1,052.79 | +11.3% | 1,089.58 | +7.5% |
| Profit before tax | 322.12 | 269.04 | +19.7% | 278.04 | +15.9% |
| Net profit for the period | 245.77 | 208.12 | +18.1% | 202.72 | +21.2% |
| Attributable to shareholders of the company | 238.43 | — | — | 196.33 | +21.4% |
| EPS, basic (₹) | 19.54 | 16.53 | +18.2% | 16.10 | +21.4% |
| Net margin (%) | 21.5 | 20.4 | 19.2 |
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,077.27 | 1,014.58 | +6.2% | 926.07 | +16.3% |
| Other income | 28.37 | 31.46 | −9.8% | 33.68 | −15.8% |
| Total income | 1,105.64 | 1,046.04 | +5.7% | 959.75 | +15.2% |
| Profit before tax | 310.56 | 275.37 | +12.8% | 225.94 | +37.5% |
| Net profit for the period | 236.03 | 212.04 | +11.3% | 162.69 | +45.1% |
| EPS, basic (₹) | 18.77 | 16.84 | +11.5% | 12.92 | +45.3% |
| Net margin (%) | 21.9 | 20.9 | 17.6 |
Consolidated
- Filed with BSE
- 31 Jul 2024, 09:29 IST
- Board meeting
- 30 Jul 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 31 Jul 2024, 09:29 IST
- Board meeting
- 30 Jul 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE